Home Newsfeeds Oppenheimer Downgrades Amyris to Perform

Oppenheimer Downgrades Amyris to Perform

Oppenheimer analyst Colin Rusch downgrades Amyris (NASDAQ:AMRS) from Outperform to Perform.

byBenzinga Newsdesk

November 9, 2022

1 minute read

Oppenheimer analyst Colin Rusch downgrades Amyris (NASDAQ:AMRS) from Outperform to Perform.

Guggenheim Maintains Buy on Progress Software, Raises Price Target to $64

By Benzinga Newsdesk

March 13, 9:49 AM

Guggenheim analyst John Healy maintains Progress Software (NASDAQ:PRGS) with a Buy and raises the price target from $60 to $64.

PRGS

Bitcoin ETF launches Are Positive For Robinhood, But Limited Direct Driver of Transaction Revenue: Analyst

By Anusuya Lahiri

February 2, 3:10 PM

Analyst Todaro maintains Hold rating on Robinhood Markets, Inc (HOOD) and modestly increases 2024 estimates, citing strong crypto transactional volumes & revenue. Shares fairly valued based on 2024 revenue assumptions.

HOOD

Creative Medical Releases Data From StemSpine Procedure For Chronic Lower Back Pain

By Vandana Singh

May 18, 1:50 PM

Creative Medical Technology Holdings Inc (NASDAQ:CELZ) announced positive topline pilot study results for the StemSpine procedure using AlloStem to treat…

CELZ

Alaska Air Group Q4 Earnings: Softening Corporate Demand And Flight Disruptions Weigh On Bottomline

By Anusuya Lahiri

January 26, 11:32 AM

Alaska Air Group, Inc (NYSE: ALK) reported fourth-quarter FY22 operating revenue growth of 31% year-over-year to $2.48 billion, missing the consensus…

ALK

Oppenheimer Downgrades Amyris to Perform

Related Posts

Guggenheim Maintains Buy on Progress Software, Raises Price Target to $64

Bitcoin ETF launches Are Positive For Robinhood, But Limited Direct Driver of Transaction Revenue: Analyst

Creative Medical Releases Data From StemSpine Procedure For Chronic Lower Back Pain

Alaska Air Group Q4 Earnings: Softening Corporate Demand And Flight Disruptions Weigh On Bottomline